Vitamin E in Atopic Dermatitis: From Preclinical to Clinical Studies

Cheryl Wei Ling Teo a,b  Shawn Han Yueh Tay c  Hong Liang Tey d–f  Yee Wei Ung b  Wei Ney Yap a,b

aResearch and Development Department, Davos Life Science, Singapore, Singapore; bResearch and Development Department, KL-Kepong Oleomas Sdn Bhd (KLK-Oleo), Selangor, Malaysia; cSchool of Biological Sciences, Nanyang Technological University, Singapore, Singapore; dNational Skin Centre, Singapore, Singapore; eLee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore; fYong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

Keywords
Vitamin E · Tocopherols · Tocotrienols · Atopic dermatitis · Atopic eczema

Abstract
Background: Oxidative stress and inflammation are some of the proposed mechanisms involved in the pathogenesis of atopic dermatitis (AD). Current pharmacotherapeutic approaches are effective yet they are not without adverse effects. Vitamin E has great potential as an adjunctive treatment for AD owing to its antioxidant and anti-inflammatory bioactivities. Summary: This review article summarizes the current available evidence from cellular, animal and clinical studies on the relationship between vitamin E and AD. The future prospects of vitamin E are also discussed. Vitamin E in practice does not show any toxicity to humans within a range of reasonable dosage. Albeit rarely, vitamin E as a contact allergen should be considered. Collectively, this review envisaged vitamin E as an adjunctive treatment for AD patients. Future research on the distinct effects of different vitamin E isoforms as well as their delivery system in skin disorders is needed.

Introduction
Atopic dermatitis (AD), the most common form of eczema, is a non-contagious, chronic pruritic skin disease that affects approximately 15–20% of children and 3–5% of adults worldwide [1]. It begins early in life, erratically regresses after puberty and some cases will continue into adulthood, affecting both physical health and social life. Although the underlying aetiopathogenesis of AD is still poorly understood, the pathophysiology evidence suggests AD as a complex multifactorial disorder, manifesting an impaired epidermal barrier and dysregulated immune response [2–4]. Recently, the role of oxidative stress (OS) in AD has been widely studied. In high amounts, reactive oxidants cause cellular damage to epidermal keratinocytes through lipid peroxidation [5]. Evidence also suggests the contribution of OS to tissue inflammation through upregulation of genes responsible for pro-inflammatory cytokines via the nuclear factor-κB pathway [6, 7].

There is currently no long-term cure for AD, and the present pharmacotherapeutic approach includes corticosteroids, calcineurin inhibitors and antihistamines [8]. While proven effective, the current available drugs are
not without adverse effects. Naturally occurring phenolic antioxidants such as vitamin E have been shown to play a modest role in AD [9–12]. “Vitamin E” is a collective term for tocopherols (TP) and tocotrienols (T3), which mainly differ in their aliphatic tail. T3 has been shown to display a superior antioxidant effect as compared to TP due to its unsaturated and isoprenoid side chain [13–15]. Apart from its antioxidant activity, vitamin E is able to suppress inflammation and upregulate gene expression of keratinocyte differentiation markers, suggesting its potential as a therapeutic agent against AD [16, 17].

The majority of AD patients are treated with oral and transdermal vitamin E. Several randomized controlled trials suggested vitamin E supplementation could improve AD clinical manifestations and inflammatory allergic responses [9, 11, 12, 18, 19]. Lately, incorporation of micronutrients in nanotechnology-based therapeutics has been shown to improve the bioavailability of poorly aqueous solubility vitamins [20]. Vitamin E nanoformulations have been found to be advantageous in enhancing the delivery efficacy and skin retention [21–23]. In this review, we aim to summarize the current available studies and evidence pertaining to the efficacy and safety for the use of vitamin E treatment in AD, and hence its future prospects.

**Literature Search**

The literature search from January 1994 through March 2019 was conducted via the PubMed/MEDLINE database using the keywords (“Vitamin E” OR “tocopherols” OR “tocotrienols”) AND (“atopic dermatitis” OR “atopic eczema” OR “eczema”). All the search results were identified by titles followed by abstracts to find articles for further full-text screening before final inclusion in the systematic review. The selection process has followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines as shown in Figure 1. A total of 25 studies (5 cellular studies, 4 animal studies and 16 human studies) met our criteria.

Most studies have used the term “vitamin E” indiscriminately. To provide the reader with clarity and a better understanding of the effects of the various isoforms of vitamin E, we will specify the isoforms of vitamin E in our discussion below unless omitted from the original papers. In such cases, we will use the general term “vitamin E” as mentioned in the original papers.

**Preclinical Evidence from Cellular Studies**

To investigate the role of vitamin E in the regulation of OS, Masaki et al. [24] cultivated HaCaT cells with α-TP for 24 h and measured the level of intracellular glutathione, a crucial protein involved in removing excess intra-
cellular reactive oxygen species. Glutathione levels were reported to increase at every tested α-TP concentration, and cells cultured with 50 μM α-TP exhibited resistance against H₂O₂. A deeper investigation on the mechanism of action of α-TP using DL-β-thionine-[S, R]-sulfoximine, an inhibitor of γ-glutamyl-cysteine synthetase, showed α-TP increases intracellular glutathione level via upregulation of the γ-glutamyl-cysteine synthetase heavy subunit mRNA [24]. In another study, Gehin et al. [25] suggested the preventive effects of vitamin E against deleterious cutaneous cell damage. A water-soluble analogue of vitamin E, Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) at 100 μM, was shown to reduce lipid peroxidation and increase enzyme activities of superoxide dismutase, glutathione reductase and glutathione peroxidase concurrently in glyphosate-based herbicide-treated keratinocytes [25]. These findings strongly suggest the effectiveness of vitamin E in suppressing OS in keratinocytes.

AD is known to be associated with keratinocyte damage and impaired skin barrier function. Transepidermal water loss (TEWL) is the functional biomarker of skin benefit. Parish et al. [26] have shown keratinocytes treated with 20 and 40 μM of α-TP for 18 days experienced a reduction in TEWL as compared to the controls.

De Pascale et al. [27] studied the transcriptional effects of natural TP analogues (α-, β-, γ-, δ-TP) in normal human keratinocytes. All TP analogues at 50 μM were able to induce peroxisome proliferator-activated receptor-γ transcriptional activity via induction of its protein levels with consequent upregulation of transglutaminase-1 gene expression. Transglutaminase-1 plays a key role in terminal keratinocyte differentiation which is essential for stratum corneum (SC) formation [27]. A similar observation was also reported by Kato and Takahashi [17]. In their study, normal human epidermal keratinocytes treated with 50 μM of sodium DL-α-tocopheryl-6-O-phosphate (a hydrophilic derivative of vitamin E) showed an increase in mRNA expression of differentiation markers, including transglutaminase-1, cytokerin-10, involucrin and loricrin. Ceramide concentration in keratinocytes, a key indicator of the skin barrier function and water-retaining properties, was also increased [17].

Considering all available preclinical cellular evidence, vitamin E seems to hold promise as a treatment for AD by means of ameliorating harmful effects of OS, reducing TEWL, upregulating the gene expression of keratinocyte differentiation markers and promoting water-holding properties. A summary of the studies showing the preclinical evidence for vitamin E in cells is presented in Table 1.

### Preclinical Evidence from Animal Studies

The role of vitamin E in relieving inflammation and erythema was studied by Hayashi et al. [16] using an NC/Nga mouse model. In their study, mice were subcutane-
uously injected in their backs with a 4% α-TP (200 mg/kg body mass) every other day for 2 weeks. Sensitization was then carried out using 5% picryl chloride (PC) solution followed by 0.05% PC to induce AD-like inflammation. Mice treated with PC without vitamin E treatment showed a decrease in vitamin E levels and a marked increase in thiobarbituric acid reactive substance levels at the stage of peak symptom severity. Conversely, changes in thiobarbituric acid reactive substance and vitamin E levels in the skin and serum were significantly inhibited in α-TP-treated mice. Furthermore, levels of the antioxidant enzymes superoxide dismutase and glutathione peroxidase increased at peak severity in vitamin E-treated mice, as opposed to control mice. Mice treated with α-TP were also found to have decreased levels of inflammation-associated factors such as immunoglobulin E (IgE), cyclooxygenase-2, tumour necrosis factor-α and nuclear factor-κB [16].

Tsuduki et al. [28] also employed an NC/Nga mouse model to study the influence of oral T3 on the symptoms of AD. The mice were supplemented with 1 mg/day of tocotrienol-rich fraction for 1 week before PC sensitization. AD was then induced in the mice using 1% PC after sensitization with 5% PC. The scratching behaviour, dermal thickening and serum histamine levels were greatly reduced in AD mice supplemented with tocotrienol-rich fraction as compared to untreated mice after 9 weeks. Further investigation into the mechanism of action showed T3 was able to suppress AD via the inhibition of protein kinase C activity. The antidegranulation, histamine reduction and protein kinase C activity suppression effects of T3 were ranked as δ-T3 > β-T3 > γ-T3 > α-T3. It is worth noting that this is the only known study to date which explored the efficacy of T3 in the direct treatment of AD.

Kato and Takahashi [17] examined the effects of sodium DL-α-tocopheryl-6-O-phosphate on the moisture-retaining properties of SC in hairless mice. The researchers discovered topical application of 1 and 2% sodium DL-α-tocopheryl-6-O-phosphate for 4 weeks effectively improved the hygroscopicity and water-holding capacity of SC by 1.5-fold. Next, they studied if the topical treatment would also affect the ceramide content in the SC. The obtained results reflected a 1.7-fold increase in ceramide content after treatment, suggesting that vitamin E could be effective in improving skin moisture retention by enhancing ceramide synthesis.

In a recent study, dogs diagnosed with AD were orally treated with α-TP (8.1 IU/kg body mass) for 8 weeks. After the course of treatment, α-TP-treated dogs were found to have significantly higher plasma vitamin E and total antioxidant capacity levels as compared to the control dogs. They were also observed to have less severe lesions and obtained lower scores on the Canine Atopic Dermatitis Extent and Severity Index-03 assessment, suggesting the effectiveness of α-TP as a treatment for AD in canines [29].

No adverse effects of vitamin E were observed in the animal studies discussed above. Collectively, vitamin E may aid in ameliorating the symptoms of AD by suppressing OS, inflammation and preventing further deterioration of the skin barrier function by restoring the water-retaining capacity of the SC. A summary of the studies showing the preclinical evidence for vitamin E in animals is presented in Table 2.

### Relationship between Vitamin E and AD in Human Studies

The following discourse is organized into 2 sections according to the relationship between vitamin E and AD in humans, that is, positive relationship (higher vitamin E intake/level, improvement in AD condition) and negligible relationship (no association between vitamin E and AD). To the best of our knowledge, there are no studies highlighting a negative relationship between vitamin E and skin health to date. In the following discussion, we refrain from using the term “effect” unless the study has established causality. For each section, the studies are arranged according to the type and level of evidence (case-control, cross-sectional or prospective studies, clinical trials).

#### Positive Relationship between Vitamin E and Skin Health

Several studies have reported a lower prevalence of AD in young children with higher antioxidant nutritional intakes. Based on the data of 180 AD and 242 non-AD children between 4 and 6 years old, Oh et al. [30] observed a lower likelihood of AD in children who consumed more dietary vitamin E, which led to higher serum α-TP levels. A similar observation was made by Okuda et al. [31] in 396 Japanese students aged between 10 and 13 years. Questionnaires and serum antioxidant analysis revealed a significant negative association between serum α-TP levels and the prevalence of AD. In another study, Lee et al. [32] investigated the relationship between α-TP and serum IgE levels in Korean children aged between 0 and 24 months who were diagnosed with AD. The findings...
showed a strong negative association between serum α-TP and IgE levels, suggesting the importance of maintaining a high serum α-TP in children diagnosed with AD. However, the study was limited to the sample size as the researchers were only able to measure serum vitamin E levels in 25 out of 119 children. This was due to the difficulty in drawing sufficient amounts of blood from children < 24 months old.

Two prospective studies were conducted to investigate the correlation of maternal vitamin E levels on their infants. In 1 study, Hoppu et al. [33] recruited atopic mothers who were near the end of gestation to assess their α- and γ-TP serum levels and the relationship with the levels in their infants. A significant correlation was detected between infants’ and mothers’ serum α- and γ-TP to fat ratios. This suggests the maternal TP status impacts that of the infant, and it is conceivable that infants whose mothers have low serum TP status may be at risk of developing atopic diseases. Martindale et al. [34] sought to examine the relationship between maternal antioxidant intake (vitamin E, vitamin C, β-carotene, selenium, magnesium, manganese, copper and zinc) in pregnancy and the prevalence of AD in the first 2 years of the infant’s life. Their findings supplement those of Hoppu et al. [33], in which vitamin E intake by atopic mothers during pregnancy was found to be negatively associated with childhood AD. The authors thus postulated maternal dietary antioxidant intake during pregnancy may reduce the risk of the child developing childhood AD [34]. In all the above case-control and prospective studies, interindividual differences in bioavailability and vitamin E supplementation were not considered. Several studies also made use of questionnaires or subjective assessments, which could undermine the accuracy of the results. Furthermore, while the aforementioned studies suggest a positive relationship between vitamin E and skin health, most did not clarify causality.

In a form of oral monotherapy, the correlation between vitamin E and dermatitis was reported by Olson et al. [35] in an observational study. A patient suffering from refractory hand dermatitis initiated self-medication with vitamin E at 400 mg for primary prevention of coronary atherogenesis. He noted his recalcitrant hand dermatitis of 4 years started to improve unexpectedly after 9 days of treatment. Withdrawing the vitamin E supplementation led to a recurrence of palmar fissuring. The symptoms were subsequently cleared again when vitamin E was re-instituted. While this is only a singular case report and is unable to prove causality, it opens the door to researching the efficacy of vitamin E as a treatment for dermatitis in humans based on its known antioxidant and anti-inflammatory properties.

To investigate the effect of oral vitamin E on patients diagnosed with AD, Tsoureli-Nikita et al. [9] conducted a single-blind placebo-controlled clinical analysis to compare subjective symptoms and serum IgE levels in 96 patients after daily treatment with 400 IU vitamin E for 8 months. The analysis showed that almost half of the
subjects treated with vitamin E had great improvement, compared to only 1 in the placebo group. Also, 14% of subjects in the vitamin E group showed almost complete remission of the disease, as compared to none in the placebo group. Serum IgE levels in the vitamin E group were also found to be lower than those of the placebo group [9].

The antioxidant activity of α-T3 was demonstrated in a clinical trial by Weber et al. [10]. The researchers applied α-T3 (5% w/v) topically on the upper back of 11 subjects for 7 days and subsequently induced SC perturbation by applying 10% benzoyl peroxide to the defined area. Results suggested α-T3 is efficacious in the prevention of lipid peroxidation but not barrier perturbation in the SC. However, this study suffers from a small sample size.

In a randomized, double-blind, placebo-controlled clinical trial conducted by Javanbakht et al. [18], 45 AD patients were divided into 4 treatment groups, each receiving either placebo, 400 IU synthetic α-TP or 1,600 IU vitamin D, with various combinations. The researchers concluded α-TP and vitamin D are equally potent in increasing erythrocyte superoxide dismutase activity in AD patients. They postulated a synergistic effect of α-TP and vitamin D on erythrocyte catalase activity [18]. Using the same model, Javanbakht et al. [11] observed a similar result in another study whereby the groups receiving either α-TP or vitamin D showed reduction in the Scoring Atopic Dermatitis index by 35.7 and 34.8%, respectively. Interestingly, the group that received both α-TP and vitamin D showed a more considerable improvement (64.3%) compared to separate supplementation.

A clinical trial performed by Shahla et al. [19] on 100 AD patients across various age groups compared the subjective effects of medication with oral vitamin E. Over a period of 8 months, 50 patients received oral vitamin E (400 IU/day), while the other 50 patients received topical corticosteroids coupled with oral antihistamines. From the results of the posttreatment questionnaire, the authors concluded vitamin E may be efficacious as a treatment for AD, with observable reductions in skin lesions and pruritus comparable to treatment with topical corticosteroid and oral antihistamines. No side effects were reported from the vitamin E treatment. However, the study was not placebo-controlled, and the dosages for topical corticosteroid and oral antihistamines were not listed. Observations and results from the clinical trial were mostly subjective and unquantified. There was no formal posttreatment clinical evaluation of the patients to validate the accuracy of observations either [19].

Jaffary et al. [12] demonstrated the relationship between oral vitamin E and AD in a double-blind, randomized, placebo-controlled trial. Sixty-five AD patients were treated with either vitamin E (400 IU/day) or placebo for 4 months in addition to the usual treatment for AD (vaseline, glycerin soap, hydroxyzine tablet and topical hydrocortisone cream 1%). The results suggested vitamin E is efficacious in improving certain AD symptoms such as itching and lesions but not sleeplessness.

Patrizi et al. [36] conducted a double-blind, randomized, controlled trial to evaluate the efficacy of a non-steroidal topical cream (MD2011001) containing vitamin E, epigallocatechin gallate and grape seed procyanidins in treating 39 patients with mild-to-moderate AD. The measurement of the severity of AD was based on the Investigator’s Global Assessment scale, and the results showed there was a significantly faster reduction in the AD-affected surface area when treated with MD2011001. However, the effect of MD2011001 cannot be attributed to vitamin E alone as the active ingredients also included other antioxidants and emollient ingredients like epigallocatechin gallate and grape seed procyanidins. It is worth noting that adverse events were observed only in this study. Adverse events were observed in 4 patients of the placebo group (irritant contact dermatitis = 1, AD flare = 2, impetigo = 1) and 7 patients of the MD2011001 group (irritant contact dermatitis with AD flare = 1, AD worsening = 3, flu-like syndrome = 1, impetigo = 2). This warrants further research on the safety and tolerability of topical vitamin E. A summary of the studies showing a positive relationship between vitamin E and skin health is presented in Table 3.

Negligible Relationship between Vitamin E and Skin Health

Three prospective studies suggested a negligible relationship between vitamin E and skin health. Miyake et al. [37] studied the diet history questionnaire of 763 Japanese mother-child pairs and assessed the relationship between dietary antioxidant (α-carotene, β-carotene, vitamin C, vitamin E and zinc) intake and symptoms of wheeze and AD. Analysis of the data revealed a significant inverse relationship between maternal vitamin E consumption during pregnancy and wheezing, but not AD. On the other hand, higher maternal intake of green and yellow vegetables, citrus fruits and β-carotene during pregnancy seemed to confer a reduced risk of AD in the infant.

This observation was also supported by Nwaru et al. [38] in their study using data from the Finnish popula-
**Table 3. A summary of the clinical studies showing a positive relationship between vitamin E and skin health**

<table>
<thead>
<tr>
<th>Researchers, year</th>
<th>Study design</th>
<th>Assessment, doses and administration</th>
<th>Positive outcomes</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oh et al. [30], 2010</td>
<td>Case-control study 180 Korean AD and 242 non-AD children (4–6 years old)</td>
<td>Dietary vitamin E</td>
<td>AD was negatively associated with intake of vitamin E</td>
<td>Unavailability of supplement intake for all micronutrients, interindividual differences in bioavailability and utilization of nutrients may have underestimated the true association between some nutrients and AD</td>
</tr>
<tr>
<td>Okuda et al. [31], 2010</td>
<td>Case-control study 396 Japanese students (10–13 years old)</td>
<td>Dietary vitamin E</td>
<td>Serum α-T, but not carotenoids, was negatively associated with the prevalence of AD</td>
<td>Unadjusted confounding variables, unavailability of supplement intake for all micronutrients and questionnaire survey may lead to imprecise results</td>
</tr>
<tr>
<td>Lee et al. [32], 2012</td>
<td>Cross-sectional study 119 Korean AD children (0–24 months old)</td>
<td>Dietary vitamin E</td>
<td>Serum vitamin E levels were inversely associated with serum total IgE and all specific IgE levels</td>
<td>Serum vitamin E was only measured in 25 out of the 119 children due to limited amount of blood drawn One-day 24-h recall is limited and may not represent the typical dietary habits of infants and children</td>
</tr>
<tr>
<td>Hoppu et al. [33], 2005</td>
<td>Prospective study 34 mothers with atopic disease and their infants</td>
<td>Serum level of vitamin E</td>
<td>Infants’ serum α- and γ-T to fat ratios were significantly correlated with maternal serum ratios Maternal tocopherol status determines that of the infant</td>
<td>Personal characteristics and lifestyle factors may influence the TP status in mothers and infants</td>
</tr>
<tr>
<td>Martindale et al. [34], 2005</td>
<td>Prospective study 1,924 mothers and their infants</td>
<td>Dietary vitamin E</td>
<td>Maternal vitamin E intake was negatively associated with the likelihood of AD during the first 2 years in children with atopic mothers</td>
<td>Confounding factors associated with socioeconomic status and lifestyle may lead to imprecise results</td>
</tr>
<tr>
<td>Olsen et al. [35], 1994</td>
<td>Observational study A 38-year-old patient with previously refractory palmar dermatitis</td>
<td>Oral softgel 400 mg/day</td>
<td>Patient’s recalcitrant hand dermatitis of 4 years cleared after initiation of oral vitamin E, recurred after the supplementation was ceased, and was cleared again with resumption of vitamin E Subsequent complete remission of signs and symptoms has been maintained with vitamin E supplementation</td>
<td>Causality was not proved</td>
</tr>
<tr>
<td>Tsoureli-Nikita et al. [9], 2002</td>
<td>Single-blind, placebo-controlled, randomized clinical trial 96 AD subjects (10–60 years old)</td>
<td>Oral softgel 400 IU/day (8 months)</td>
<td>Vitamin E supplementation improved AD clinical manifestations Serum vitamin E level was inversely associated with serum IgE levels, with a total decrease of 62% based on initial conditions</td>
<td>Personal subjective assessment of the treatment, exacerbating factors and the types of remedies may lead to imprecise evaluation</td>
</tr>
<tr>
<td>Weber et al. [10], 2003</td>
<td>Double-blind, placebo-controlled, clinical trial 11 subjects (20–34 years old)</td>
<td>Topical oil 5% w/v (7 days)</td>
<td>a-T3 supplementation significantly mitigated the BPO-induced SC barrier perturbation caused by lipid peroxidation</td>
<td>Small sample size may reduce the power and reliability of the study</td>
</tr>
<tr>
<td>Javanbakht et al. [11], 2010</td>
<td>Double-blind, placebo-controlled, randomized clinical trial 45 AD patients (13–45 years old)</td>
<td>Oral softgel 600 IU/day (60 days)</td>
<td>Vitamin E and/or D supplementation alleviated AD through deactivating free radicals by promoting antioxidant enzymes erythrocyte SOD and catalase activities in AD patients</td>
<td>Small sample size may reduce the power and reliability of the study</td>
</tr>
<tr>
<td>Javanbakht et al. [18], 2011</td>
<td>Double-blind, placebo-controlled, randomized clinical trial 45 AD patients (13–45 years old)</td>
<td>Oral softgel 600 IU/day (60 days)</td>
<td>Vitamin E and/or D supplementation improved clinical manifestations of AD by reducing SCORAD Plasma α-TP was negatively associated with SCORAD, intensity, objective and extent</td>
<td>Small sample size and confounding factor associated with the potencies of topical corticosteroid may reduce the reliability of the study</td>
</tr>
<tr>
<td>Shahla et al. [19], 2013</td>
<td>Randomized clinical trial 100 AD patients (3–40 years old)</td>
<td>Oral softgel 400 IU/day (8 months)</td>
<td>Vitamin E may have the same effect as common treatment with topical corticosteroid and oral antihistamines in improving the clinical manifestations of AD</td>
<td>Non-placebo-controlled trial disallowed estimation of the treatment sensitivity</td>
</tr>
<tr>
<td>Jaffary et al. [12], 2015</td>
<td>Double-blind, placebo-controlled, randomized clinical trial 65 AD patients (10–50 years old)</td>
<td>Oral softgel 400 IU/day (4 months)</td>
<td>Itching, extent of lesions, and SCORAD index improvement was significantly higher in vitamin E-treated AD patients</td>
<td>Unadjusted confounding variables may lead to imprecise results</td>
</tr>
<tr>
<td>Patrizi et al. [36], 2016</td>
<td>Double-blind, placebo-controlled, randomized clinical trial 39 AD patients (6–69 years old)</td>
<td>Topical cream (28 days) MD2011001 cream containing vitamin E, EGC, and grape seed procyanidins</td>
<td>Vitamin E-containing MD2011001 cream improved the restoration and the integrity of the epidermal skin barrier and cutaneous inflammatory symptoms in AD patients Mild to moderate side effects were reported</td>
<td>Small sample size, unadjusted confounding variables and unavailability of doses for vitamin E may lead to imprecise results</td>
</tr>
</tbody>
</table>

α-T3, α-tocotrienol; α-TP, α-tocopherol; γ-TP, γ-tocopherol; AD, atopic dermatitis; BPO, benzoyl peroxide; EGC, epigallocatechin gallate; IgE, immunoglobulin E; SC, stratum corneum; SCORAD, Scoring Atopic Dermatitis; SOD, superoxide dismutase.
tion-based birth cohort nutritional study with a 5-year follow-up. The researchers proposed no significant association between maternal intake of antioxidants (α-carotene, β-carotene, vitamin C, α-TP, γ-TP, zinc, copper, selenium, magnesium, calcium, manganese, folic acid, riboflavin and retinol) and the risk of atopic diseases such as AD, except for the dietary intake of magnesium, which had an independent association with protection against AD in children.

Another study by Nwaru et al. [39] sought to investigate the association between serum vitamin E (α- and γ-TP) concentrations and the development of atopic diseases up to 6 years in life. Measurements of serum vitamin E levels and periodic observation for symptoms of various atopic diseases such as wheezing, asthma and AD starting from year 1 were performed in 1,133 mother-child pairs. No statistically significant associations between α- or γ-TP serum concentrations and atopic sensitization or AD were observed. However, serum vitamin E was only measured at one time point at year 1. Repeated measurements of serum vitamin E levels over the years might have provided a more accurate analysis of the relationship between serum vitamin E levels and AD. A summary of the studies showing a negligible relationship between vitamin E and skin health is presented in Table 4.

**Table 4. A summary of the studies showing a negligible relationship between vitamin E and skin health**

<table>
<thead>
<tr>
<th>Researchers, year</th>
<th>Study design</th>
<th>Assessment, doses and administration</th>
<th>Negligible outcomes</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miyake et al. [37], 2009</td>
<td>Prospective study 763 Japanese mothers and their children</td>
<td>Dietary vitamin E</td>
<td>Maternal vitamin E consumption during pregnancy was significantly inversely related to the risk of infantile wheeze but not AD</td>
<td>Unadjusted confounding variables and self-administered diet history questionnaire may lead to imprecise results</td>
</tr>
<tr>
<td>Nwaru et al. [38], 2011</td>
<td>Prospective study 2,441 Finnish mothers and their children</td>
<td>Dietary vitamin E</td>
<td>Maternal intake of vitamin E was not significantly associated with the risk of asthma, rhinitis or AD in the children</td>
<td>Unadjusted confounding variables and self-administered diet history questionnaire may lead to imprecise results</td>
</tr>
<tr>
<td>Nwaru et al. [39], 2013</td>
<td>Prospective study 1,133 European mothers and their children</td>
<td>Serum level of vitamin E</td>
<td>No statistically significant associations between serum vitamin E concentrations at year 1 and AD</td>
<td>Unadjusted confounding variables and self-administered questionnaire may lead to imprecise results</td>
</tr>
</tbody>
</table>

AD, atopic dermatitis.

Perspective

The term vitamin E has been used indiscriminately in many studies, commonly referring to α-TP. This could be attributed to the disproportionately large number of studies performed on α-TP as it is the most abundant form of vitamin E found in nature and the human body. Researchers should be more specific in the description of the forms of vitamin E employed in their studies. While most of the current studies have suggested the effectiveness of α-TP and its derivative forms in AD, not many have explored the efficacy of T3. T3 possesses powerful neuroprotective, cholesterol-lowering, anti-aging, anti-inflammatory and anticancer properties that are often not fully exhibited by TP [40–44]. It is thus worth further investigating the specific mechanism of action of different T3 isoforms in treating AD.

Administration of vitamin E in clinical studies is predominantly oral and transdermal. Although it has been postulated to be more potent in its antioxidative and anti-inflammatory abilities, T3 may suffer from the hindrance of poor pharmacokinetic profile and low bioavailability as compared to α-TP. This is mainly due to the lack of affinity to α-TP transport protein and catabolization by ω-hydroxylase in the body [45, 46]. Nanotechnology interventions, for example, the nanoparticles, nanoemulsions and liposomes, could be further researched to enhance the encapsulation, stability and permeation of natural vitamin E.

On the other hand, the topical use of vitamin E has raised concern about allergic contact dermatitis (ACD) in AD patients. Contact allergy to vitamin E and its derivatives, mainly the synthetic form, has been described in a few individual case reports. A study conducted in 1991 detailed 4 cases of ACD caused by tocopheryl acetate 10% petrolatum-containing cream. Erythema, urticarial papules and papulovesicular dermatitis on different parts of the body are among the clinical observations using patch tests. All patients reported no recurrence of allergic symp-
Vitamin E and Eczema

In another case, patch testing in a patient with erythema multiforme-like eruption indicated a positive allergic reaction to tocopherol acetate 5% petrolatum [48]. Apart from the topical application, dietary vitamin E was also reported as the cause of ACD. In a recent case, a patient with long-standing AD that fails to improve with topical therapy, which include ammonium lactate, hypoallergenic emollients, hydrocortisone cream, fluocinolone ointment and steroids, experienced a dramatic improvement of his widespread AD after avoiding TP from diet and topical products. His AD recurred following reintroduction of dietary products high in TP, and resolution of the dermatitis was again achieved through allergen avoidance [49]. Although vitamin E has been described as the cause of ACD in some sporadic cases, the incident rate is fairly low despite its widespread use [47, 50, 51].

The skin and gut microbiomes are intimately linked via the “skin-gut axis” and exhibit several comorbidities [52, 53]. AD patients were reported to have a shift in their skin and gut microbial diversity, where that of the bacterial commensals is lower and that of the pathogens higher than in healthy individuals [54, 55]. The density of pathogenic *Staphylococcus* genera especially *S. aureus* is higher while *Cutibacterium, Streptococcus, Acinetobacter, Corynebacterium* and *Prevotella* are declined during an AD flare [55, 56]. *S. aureus* is a superantigen that aggravates AD by producing several virulent agents such as α-toxin that impairs the skin barrier or protein A that triggers an inflammatory response from keratinocytes and proteases that dissolves the SC [57–60]. Disequilibrium of the gut microbiome could impact the development of AD through immunological, metabolic and neuroendocrine pathways [61–65]. Bacterial colonization in the gut during infancy shaped the development of the immune system later in life [66, 67]. Infants with low *Bifidobacterium, Bacteroides, Akkermansia* and *Faecalibacterium* density in the gut have been associated with subsequent AD. In addition, it was found that the abundances of *S. aureus, Clostridium difficile* and *Escherichia coli* are higher in AD infants compared to healthy controls [68–71]. Rebalancing the microbiome will be essential to maintain a healthy community in the skin and gut.

---

**Fig. 2.** Summary of vitamin E efficacy in atopic dermatitis. TEWL, transepidermal water loss; SCORAD, Scoring Atopic Dermatitis index; CADESI-03, Canine Atopic Dermatitis Extent and Severity Index-03; GSH, glutathione; GPx, glutathione peroxidase; SOD, superoxide dismutase; TAC, total antioxidant capacity; NF-κB, nuclear factor-κB; COX-2, cyclo-oxygenase-2; TNF-α, tumour necrosis factor-α; PKC, protein kinase C; TGM-1, transglutaminase-1; K-10, cytokeratin-10; IVL, involucrin; LOR, loricrin.

---
Conclusion

The progression of AD has been attributed to OS, inflammation and degenerating skin barrier function. This is evidenced by increased oxidative damage, inflammation-associated markers, serum IgE levels, TEWL and reduced antioxidant levels. The existing studies largely suggest a positive relationship between vitamin E and skin health as illustrated in Figure 2. As such, vitamin E holds promise as an adjunctive treatment for AD and other skin disorders stemming from OS and inflammation. Topical application of 5% and a daily dosage up to 600 IU of vitamin E can be considered safe in humans. Albeit rare, the risk of contact allergy to topical vitamin E should not be disregarded. The different isoforms of vitamin E and their risk of contact allergy to topical vitamin E should not be minimized. The rest of the authors have no conflicts of interest to declare.

Funding Sources

This work was financially supported by a research grant from KL-Kepong Oleomas Sdn Bhd (KLK Oleo) to Davos Life Science Pte Ltd.

Author Contributions

C.W.L.T. and S.H.Y.T. were responsible for acquisition and interpretation of data and drafting the manuscript for this work. H.L.T., Y.W.U. and W.N.Y. critically revised the work for important intellectual content and flow of ideas. All authors provided final approval of the version to be published and agree to be accountable for all aspects of the work.

References

Vitamin E and Eczema


